Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sunshine Heart, Inc. Announces Conditional Approval From FDA For Next Generation C-Pulse System Driver


Sunday, 5 Aug 2012 06:41pm EDT 

Sunshine Heart, Inc. announced that it has received conditional approval from the United States Food and Drug Administration (FDA) for its next generation C-Pulse System driver. This new iteration is designed to provide moderate to severe heart failure patients with enhanced patient comfort and performance. Conditional approval from the FDA allows the Company to use this next generation driver for investigational purposes in the United States at all sites that are enrolled in Sunshine Heart's North American feasibility trial. 

Company Quote

5.26
-0.04 -0.75%
11 Jul 2014